Immunome Financial Statements (IMNM)
|
|
|
|
Report date
|
|
|
31.12.2019 |
25.03.2021 |
28.03.2022 |
16.03.2023 |
28.03.2024 |
|
13.11.2024 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
0.000 |
0.000 |
0.000 |
0.000 |
14.0 |
|
10.1 |
|
Operating Income, bln rub |
|
|
-10.3 |
-12.3 |
-25.2 |
-36.9 |
-109.5 |
|
-317.5 |
|
EBITDA, bln rub |
? |
|
-9.72 |
-17.0 |
-23.9 |
-36.3 |
-28.3 |
|
-119.9 |
|
Net profit, bln rub |
? |
|
-10.6 |
-17.1 |
-24.5 |
-37.5 |
-106.8 |
|
-305.3 |
|
|
OCF, bln rub |
? |
|
-9.60 |
-12.1 |
-18.2 |
-28.7 |
-7.57 |
|
-86.2 |
|
CAPEX, bln rub |
? |
|
0.233 |
0.586 |
0.079 |
0.248 |
0.831 |
|
6.40 |
|
FCF, bln rub |
? |
|
-9.83 |
-12.7 |
-18.3 |
-28.9 |
-8.40 |
|
-92.6 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
10.3 |
12.3 |
25.2 |
36.9 |
122.8 |
|
326.4 |
|
Cost of production, bln rub |
|
|
0.615 |
0.755 |
0.755 |
0.631 |
22.9 |
|
1.19 |
|
R&D, bln rub |
|
|
8.82 |
7.49 |
14.1 |
23.3 |
80.8 |
|
253.0 |
|
Interest expenses, bln rub |
|
|
0.106 |
0.038 |
0.010 |
0.005 |
0.000 |
|
0.201 |
|
|
Assets, bln rub |
|
|
5.06 |
44.5 |
57.9 |
24.0 |
148.5 |
|
256.9 |
|
Net Assets, bln rub |
? |
|
-35.6 |
41.3 |
48.2 |
16.7 |
119.9 |
|
214.9 |
|
Debt, bln rub |
|
|
0.564 |
0.613 |
0.317 |
0.293 |
1.65 |
|
2.46 |
|
Cash, bln rub |
|
|
2.54 |
39.8 |
49.2 |
20.3 |
138.1 |
|
240.1 |
|
Net debt, bln rub |
|
|
-1.98 |
-39.2 |
-48.9 |
-20.0 |
-136.5 |
|
-237.7 |
|
|
Ordinary share price, rub |
|
|
|
9.68 |
13.0 |
2.21 |
10.7 |
|
2.50 |
|
Number of ordinary shares, mln |
|
|
5.74 |
10.1 |
11.5 |
12.1 |
19.8 |
|
60.2 |
|
|
Market cap, bln rub |
|
|
0 |
98 |
150 |
27 |
212 |
|
151 |
|
EV, bln rub |
? |
|
-2 |
59 |
101 |
7 |
76 |
|
-87 |
|
Book value, bln rub |
|
|
-36 |
41 |
48 |
17 |
120 |
|
215 |
|
|
EPS, rub |
? |
|
-1.84 |
-1.69 |
-2.12 |
-3.09 |
-5.38 |
|
-5.07 |
|
FCF/share, rub |
|
|
-1.71 |
-1.26 |
-1.59 |
-2.39 |
-0.42 |
|
-1.54 |
|
BV/share, rub |
|
|
-6.20 |
4.09 |
4.18 |
1.37 |
6.04 |
|
3.57 |
|
|
EBITDA margin, % |
? |
|
|
|
|
|
-201.7% |
|
-1 183% |
|
Net margin, % |
? |
|
|
|
|
|
-761.9% |
|
-3 015% |
|
FCF yield, % |
? |
|
|
-13.0% |
-12.2% |
-108.0% |
-3.96% |
|
-61.5% |
|
ROE, % |
? |
|
29.6% |
-41.4% |
-50.8% |
-225.3% |
-89.1% |
|
-142.1% |
|
ROA, % |
? |
|
-208.5% |
-38.5% |
-42.2% |
-156.0% |
-71.9% |
|
-118.9% |
|
|
P/E |
? |
|
0.00 |
-5.72 |
-6.11 |
-0.71 |
-1.99 |
|
-0.49 |
|
P/FCF |
|
|
0.00 |
-7.69 |
-8.17 |
-0.93 |
-25.3 |
|
-1.63 |
|
P/S |
? |
|
|
|
|
|
15.1 |
|
14.9 |
|
P/BV |
? |
|
0.00 |
2.37 |
3.10 |
1.61 |
1.77 |
|
0.70 |
|
EV/EBITDA |
? |
|
0.20 |
-3.45 |
-4.20 |
-0.19 |
-2.68 |
|
0.73 |
|
Debt/EBITDA |
|
|
0.20 |
2.30 |
2.04 |
0.55 |
4.83 |
|
1.98 |
|
|
R&D/CAPEX, % |
|
|
3 787% |
1 277% |
17 861% |
9 384% |
9 723% |
|
3 956% |
|
|
CAPEX/Revenue, % |
|
|
|
|
|
|
5.93% |
|
63.1% |
|
| Immunome shareholders |
